Evidence map›Paper›PMID 34071728›Full record

ArticleMarine drugs2021

Mining Indonesian Microbial Biodiversity for Novel Natural Compounds by a Combined Genome Mining and Molecular Networking Approach.

Ira Handayani, Hamada Saad, Shanti Ratnakomala, Puspita Lisdiyanti, Wien Kusharyoto, Janina Krause, Andreas Kulik, Wolfgang Wohlleben, Saefuddin Aziz, Harald Gross and 3 more

Abstract read
In one paragraph

Article in Marine drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Biodiversity and Natural Product Potential of Indonesian Actinomycetes.Journal of microbiology and biotechnology · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ira HandayaniDepartment of Microbiology/Biotechnology, Interfaculty Institute of Microbiology and Infection Medicine, Tübingen (IMIT), Cluster of Excellence 'Controlling Microbes to Fight Infections', University of Tübingen, Auf der Morgenstelle 28, 72076 Tübingen, Germany.
Hamada SaadDepartment of Pharmaceutical Biology, Institute of Pharmaceutical Sciences, University of Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany.
Shanti RatnakomalaResearch Center for Biology, Indonesian Institute of Sciences (LIPI), Jl. Raya Jakarta-Bogor KM.46, Cibinong, West Java 16911, Indonesia.ORCID 0000-0003-4576-4728
Puspita LisdiyantiResearch Center for Biotechnology, Indonesian Institute of Sciences (LIPI), Jl. Raya Jakarta-Bogor KM.46, Cibinong, West Java 16911, Indonesia.
Wien KusharyotoResearch Center for Biotechnology, Indonesian Institute of Sciences (LIPI), Jl. Raya Jakarta-Bogor KM.46, Cibinong, West Java 16911, Indonesia.
Janina KrauseDepartment of Microbiology/Biotechnology, Interfaculty Institute of Microbiology and Infection Medicine, Tübingen (IMIT), Cluster of Excellence 'Controlling Microbes to Fight Infections', University of Tübingen, Auf der Morgenstelle 28, 72076 Tübingen, Germany.
Andreas KulikDepartment of Microbiology/Biotechnology, Interfaculty Institute of Microbiology and Infection Medicine, Tübingen (IMIT), Cluster of Excellence 'Controlling Microbes to Fight Infections', University of Tübingen, Auf der Morgenstelle 28, 72076 Tübingen, Germany.ORCID 0000-0002-6914-7313
Wolfgang WohllebenDepartment of Microbiology/Biotechnology, Interfaculty Institute of Microbiology and Infection Medicine, Tübingen (IMIT), Cluster of Excellence 'Controlling Microbes to Fight Infections', University of Tübingen, Auf der Morgenstelle 28, 72076 Tübingen, Germany.
Saefuddin AzizDepartment of Pharmaceutical Biology, Institute of Pharmaceutical Sciences, University of Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany.
Harald GrossDepartment of Pharmaceutical Biology, Institute of Pharmaceutical Sciences, University of Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany.ORCID 0000-0002-0731-821X
Athina GavriilidouApplied Natural Products Genome Mining, Interfaculty Institute of Microbiology and Infection Medicine Tübingen (IMIT), Cluster of Excellence 'Controlling Microbes to Fight Infections', University of Tübingen, Auf der Morgenstelle 28, 72076 Tübingen, Germany.ORCID 0000-0002-6805-3868
Nadine ZiemertApplied Natural Products Genome Mining, Interfaculty Institute of Microbiology and Infection Medicine Tübingen (IMIT), Cluster of Excellence 'Controlling Microbes to Fight Infections', University of Tübingen, Auf der Morgenstelle 28, 72076 Tübingen, Germany.ORCID 0000-0002-7264-1857
Yvonne MastDepartment of Microbiology/Biotechnology, Interfaculty Institute of Microbiology and Infection Medicine, Tübingen (IMIT), Cluster of Excellence 'Controlling Microbes to Fight Infections', University of Tübingen, Auf der Morgenstelle 28, 72076 Tübingen, Germany.ORCID 0000-0003-3099-5777

Funding

Bundesministerium für Bildung und Forschung 16GW0124KDeutsche Forschungsgemeinschaft 398967434-TRR 261Deutscher Akademischer Austauschdienst PKZ 91613866Deutsches Zentrum für Infektionsforschung TTU 09.811Indonesian Ministry for Research and Technology World Bank Loan No. 8245-ID
6 · The paper itself

Abstract

Indonesia is one of the most biodiverse countries in the world and a promising resource for novel natural compound producers. Actinomycetes produce about two thirds of all clinically used antibiotics. Thus, exploiting Indonesia's microbial diversity for actinomycetes may lead to the discovery of novel antibiotics. A total of 422 actinomycete strains were isolated from three different unique areas in Indonesia and tested for their antimicrobial activity. Nine potent bioactive strains were prioritized for further drug screening approaches. The nine strains were cultivated in different solid and liquid media, and a combination of genome mining analysis and mass spectrometry (MS)-based molecular networking was employed to identify potential novel compounds. By correlating secondary metabolite gene cluster data with MS-based molecular networking results, we identified several gene cluster-encoded biosynthetic products from the nine strains, including naphthyridinomycin, amicetin, echinomycin, tirandamycin, antimycin, and desferrioxamine B. Moreover, 16 putative ion clusters and numerous gene clusters were detected that could not be associated with any known compound, indicating that the strains can produce novel secondary metabolites. Our results demonstrate that sampling of actinomycetes from unique and biodiversity-rich habitats, such as Indonesia, along with a combination of gene cluster networking and molecular networking approaches, accelerates natural product identification.

Indexed as

Anti-Bacterial AgentsBiological ProductsGram-Positive BacteriaBiodiversityDrug DiscoveryGenome, BacterialGram-Negative BacteriaIndonesiaMultigene FamilySecondary MetabolismAnti-Bacterial AgentsBiological Productsbioactivitybiodiversitydrug screeninggene cluster networkingGNPSIndonesianovel antibiotics

Identifiers

PMID34071728
PMCPMC8227522

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.